Anti-Cisplatin modified DNA antibody [CP9/19] (ab103261)

Overview

  • Product nameAnti-Cisplatin modified DNA antibody [CP9/19]
  • Description
    Rat monoclonal [CP9/19] to Cisplatin modified DNA
  • Tested applicationsSuitable for: ELISA, Flow Cyt, Dot blotmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Cisplatin Modified Native DNA.

  • Positive control
    • RNA/DNA.
  • General notes


    This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferPreservative: None
    Constituents: PBS
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Primary antibody notesThis antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.
  • ClonalityMonoclonal
  • Clone numberCP9/19
  • MyelomaY3/Ag1.2.3
  • IsotypeIgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab103261 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use at an assay dependent concentration.
Flow Cyt Use at an assay dependent concentration. PubMed: 23370278Ab37371-Rat monoclonal IgG, is suitable for use as an isotype control with this antibody.

ab37371-Rat polyclonal IgG, is suitable for use as an isotype control with this antibody.
Dot blot Use at an assay dependent concentration. PubMed: 25356874

Anti-Cisplatin modified DNA antibody [CP9/19] images

  • ab103261 staining Cisplatin modified DNA in human ovarian cancer cell line A2780 by Flow Cytometry. Cells in culture were detached by accutase treatment, fixed with 70% ehtanol for 30 min at 4°C and permeabilized with 100ug/ml digitonin in PBS. The sample was incubated with the primary antibody (1/200 in PBS + 1% FBS) for 18 hours at 4°C. A FITC-conjugated rabbit anti-rat IgG H&L polyclonal (1/200) was used as the secondary antibody. Gating Strategy: FITC positive cells.

    The sh2 represents the gene knock down cell line which showed positive staining with anti-cisplatin adduct antibody upon cisplatin treatment, whereas the control cells (cis-R, resistant to cisplatin) did not show any staining with anti-cis adduct antibody upon cisplatin treatment.

    See Abreview

References for Anti-Cisplatin modified DNA antibody [CP9/19] (ab103261)

This product has been referenced in:
  • Rocha CR  et al. Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. Cell Death Dis 5:e1505 (2014). Dot blot, ICC/IF ; Human . Read more (PubMed: 25356874) »
  • Lundholm L  et al. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest. Cell Death Dis 4:e478 (2013). Flow Cyt ; Human . Read more (PubMed: 23370278) »

See all 4 Publications for this product

Product Wall

Application Flow Cytometry
Sample Human Cell (human ovarian cancer cell line A2780)
Permeabilization Yes - 100ug/ml digitonin in PBS
Gating Strategy FITC positive cells
Specification human ovarian cancer cell line A2780
Preparation Cell harvesting/tissue preparation method: Cells in culture detached by accutase treatment
Sample buffer: PBS
Fixation 70% ehtanol for 30 min at 4 degrees
Username

Abcam user community

Verified customer

Submitted Apr 16 2015

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (ovarian cancer A2780 cell line)
Specification ovarian cancer A2780 cell line
Permeabilization Yes - 0.1% digitonin in PBS
Fixative 70% ethanol
Username

Abcam user community

Verified customer

Submitted Aug 25 2014

Regarding the question of whether ab103261 (Anti-Cisplatin modified DNA antibody [CP9/19]) recognizes adducts in chromatin or pure DNA, the antibody was raised against purified drug-modified DNA. For a number of reasons one would expect adducts on DNA ...

Read More

Thank you for your recent telephone enquiry and for your patience.

I apologize for the long delay in getting back to you. We have been waiting to receive further information from the originator of this antibody.

I am sorry to conf...

Read More

Thisantibody targets adducts present in polymeric DNA.


For any further information I would suggest the reference by Tilby et al. A pubmed link to this paper can be found under the 'Specific references' tab on the online product datashee...

Read More

Thank you very much for your interest in ab103261.

To our knowledge, ab103261 has not been tested in IHC and thereforewe do not have any protocol suggestions.

I can offer a discount off a future purchase if you buy ab103261 now, te...

Read More
Application ELISA
Sample Human Cell (melanoma)
Specification melanoma
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 0.74µg/mL · Temperature: 20°C
Type Direct
Username

Abcam user community

Verified customer

Submitted May 04 2012

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"